RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer

Поделиться
HTML-код
  • Опубликовано: 15 фев 2024
  • Dr. Christopher M. Gallagher discusses real-world evidence supporting CDK4/6 inhibitor use in HR+ metastatic breast cancer.
    This video is part of a larger CE/CME Certified program entitled: RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer. You can receive free CME credit, view this video, and download slides from the presentation at www.mededonthego.com/Video/pr...

Комментарии •